Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch, Zingo, a fast-acting, needle-free, local anesthetic, for the pediatric indication. Additional operating expenses related to the ongoing development of Adlea, which is being evaluated in Phase 3 trials for the treatment of acute pain following total knee replacement surgeries and bunionectomy surgeries.
For the second quarter of 2008, the net loss was $21.9 million, or $0.54 per share. In the second quarter of 2007, the net loss was $13.8 million, or $0.51 per share. The net loss for the six months ended June 30, 2008 was $43.4 million, or $1.08 per share, and for the six months ended June 30, 2007, the net loss was $25.5 million or $0.93 per share.
As of June 30, 2008, cash, cash equivalents and investments were $48.7
million compared to $90.8 million at December 31, 2007. The company
believes it has sufficient resources to fund anticipated expenses for the
remainder of 2008 and into 2009.
Commercial and Product Development Updates:
-- Following the Zingo U.S. commercial launch in late June, Anesiva began
supplying hospitals in its target pediatric market. The early phase of
the Zingo launch is focused on supporting initial product experiences
and formulary review and acceptance processes in these institutions.
Commenting on the initial Zingo launch, Nancy E. Donahue, senior vice
president, sales and marketing, said, "While it is too early to provide
meaningful sales metrics as we are just six weeks into the launch, initial
qualitative feedback from healthcare providers who have used Zingo suggests
that they are very pleased with its performance and ease of use. We
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved